Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved treatments.
Aficamten is already approved under the brand name Myqorzo for obstructive hypertrophic cardiomyopathy, or oHCM, in which thickened heart muscle restricts blood flow. Cytokinetics now wants to extend its use to non-obstructive hypertrophic cardiomyopathy, or nHCM, where the heart muscle thickens without creating that obstruction.
The study achieved its main objectives and showed improvements across several measures, but the absence of significant benefits involving heart structure or cardiovascular events, as well as the occurrence of heart-failure events, left investors questioning the strength of the results.
Bull Case
The late-stage trial met its two primary goals by improving heart-failure symptoms and patients’ quality of life. Cytokinetics had announced those top-line findings earlier in 2026, while the newly presented details provide a broader view of the treatment’s effects. In the 517-patient study, 53% of participants receiving aficamten achieved meaningful improvements in at least three of five important disease areas, compared with 13% of patients receiving a placebo, with the measured areas including stamina, symptom relief, and heart strain.
That 40-percentage-point difference suggests aficamten’s benefits were not confined to a single measure. Cytokinetics also said the drug significantly improved patients’ symptoms and exercise capacity, supporting its planned effort to secure an expanded indication. The company intends to submit a supplemental US marketing application during the fourth quarter of 2026. If the FDA accepts the evidence and approves the application, Cytokinetics could bring a treatment into an nHCM market that currently lacks an approved therapy.
The commercial expectations are substantial. Barclays analysts forecast more than $5 billion in peak sales for Myqorzo and expect Cytokinetics could have the nHCM market to itself for several years. They also believe an nHCM approval could create a “halo effect” that supports sales in the drug’s existing oHCM indication. The data may have implications for Cytokinetics’ broader pipeline as well. B. Riley analysts said the aficamten results could help validate ulacamten, the company’s next-generation treatment being developed for heart failure with preserved ejection fraction.
Bear Case
The trial did not demonstrate significant improvement in the heart’s structure or show that aficamten delayed cardiovascular events. That limits the evidence to improvements in symptoms, exercise capacity, and quality of life rather than confirming an effect on those longer-term outcomes. Safety is another important concern. Approximately 10% of patients experienced a potentially dangerous decline in the heart’s pumping capacity, and 12 heart-failure events occurred during the study.
Chief Medical Officer Steve Heitner told Reuters that there was an imbalance in heart-failure events early in the trial, which he attributed to a rigid study-dosing algorithm that removed clinical judgment, and said physicians would manage dosing in practice by monitoring patients’ symptoms. That is management’s explanation, however, and regulators will independently evaluate the safety evidence.
Investors also appeared disappointed by the magnitude of the benefit. Cytokinetics shares fell 6% following the detailed presentation, as analysts focused on what Reuters described as modest efficacy and safety concerns. Furthermore, a potential first-mover advantage may not last indefinitely. Bristol Myers Squibb plans to begin a late-stage nHCM study of Camzyos later in 2026, and Barclays’ expectation that Cytokinetics could control the market for several years is an analyst forecast, not a guaranteed competitive outcome.
Conclusion
Aficamten produced statistically significant improvements and met the trial’s primary goals in a disease without an approved treatment. Those results give Cytokinetics a credible foundation for its planned fourth-quarter application.
The FDA will nevertheless have to weigh meaningful symptom and quality-of-life improvements against the lack of significant structural or cardiovascular-event benefits and the observed safety findings. Aficamten could open a valuable new market, but regulatory review will determine whether the overall benefit-risk profile supports approval.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
